Framework of treating Alzheimer’s dementia  

作　　者：Yuan-Han Yang Rajka Liscic Jacqueline Dominguez 

机构地区：[1]Department of Neurology,Kaohsiung Municipal Ta-Tung Hospital,Taiwan,China [2]Department of Neurology,Kaohsiung Medical University Hospital,Kaohsiung,Taiwan,China [3]Neuroscience Research Center,Kaohsiung Medical University,Kaohsiung City,Taiwan,China [4]Department of Neurology,Johannes Kepler University Linz,Austria [5]Institute for Neurosciences,St.Luke's Medical Center,Quezon City,Philippines

出　　处：《Brain Science Advances》2019年第2期82-93,共12页神经科学（英文）

基　　金：the support by Neuroscience Research Center,Kaohsiung Medical University,KMU-TC108B01.

摘　　要：Current treatment paradigm in Alzheimer’s disease(AD)involves multiple approaches combining pharmacological and nonpharmacological intervention to mitigate the clinical symptoms,slow the progressive loss of cognitive and functional abilities,or modify the disease course.So far,beyond anti-cholinesterase inhibitors(ACh EIs),donepezil,rivastigmine,galantamine,and antagonist of N-methyl-D-aspartic acid(NMDA)receptor,there are no newly approved medicines to treat AD.Under pharmacological treatment,the personal characteristic and the intra-individual therapeutic evaluations to examine various cognitive domains,behavioral and psychological problems,and global function should be considered when choosing any of ACh EIs.The use of optimal dosage referring to the expected clinical outcomes and currently reported deficits from patient with AD has become an important issue in clinical treatment.Establishing and maintaining a strong therapeutic alliance to physician,patient,and caregiver is crucial and central to the comprehensive care in AD.Current treatment paradigm in Alzheimer’s disease(AD) involves multiple approaches combining pharmacological and nonpharmacological intervention to mitigate the clinical symptoms, slow the progressive loss of cognitive and functional abilities, or modify the disease course. So far, beyond anti-cholinesterase inhibitors(ACh EIs), donepezil, rivastigmine, galantamine, and antagonist of N-methyl-D-aspartic acid(NMDA) receptor, there are no newly approved medicines to treat AD. Under pharmacological treatment, the personal characteristic and the intra-individual therapeutic evaluations to examine various cognitive domains, behavioral and psychological problems, and global function should be considered when choosing any of ACh EIs. The use of optimal dosage referring to the expected clinical outcomes and currently reported deficits from patient with AD has become an important issue in clinical treatment. Establishing and maintaining a strong therapeutic alliance to physician, patient, and caregiver is crucial and central to the comprehensive care in AD.

关 键 词：DONEPEZIL RIVASTIGMINE GALANTAMINE MEMANTINE Alzheimer’s disease 

分 类 号：R749.16[医药卫生—神经病学与精神病学]